Thromb Haemost 1988; 60(01): 079-082
DOI: 10.1055/s-0038-1647639
Original Article
Schattauer GmbH Stuttgart

Circulating Osteocalcin During Oral Anticoagulant Therapy

L J M van Haarlem
The Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
,
M H J Knapen
The Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
,
K Hamulyák
The Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
,
C Vermeer
The Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 16 February 1988

Accepted after revision 14 April 1988

Publication Date:
30 June 2018 (online)

Zoom Image

Summary

In this paper we present the following observations:

1) In sheep vitamin K-antagonists like phenprocoumon induce a decrease of the serum levels of osteocalcin (bone Gla-protein) and of the affinity of the circulating osteocalcin for hydroxyapatite.

2) In sheep vitamin K counteracts the effect of phen-procoumon on the blood coagulation system, but not that on the osteocalcin production.

3) In human subjects vitamin K-antagonists also lead to decreased levels of serum osteocalcin and a low affinity of the protein for hydroxyapatite.

4) These two variables reached steady-state levels within 24 h after the start of oral anticoagulant treatment and - at continu-ation of the therapy - they remained low for at least several years.